Roivant Sciences Ltd Ordinary Shares ROIV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Trading Information
- Previous Close Price
- $40.67
- Day Range
- $39.88–41.37
- 52-Week Range
- $19.96–42.50
- Bid/Ask
- $38.55 / $41.50
- Shares Outstanding
- 724.56M
- Market Cap
- $29.84B
- Volume/Avg
- 11M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 716.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.67%
Company Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 721
- Website
- https://www.roivant.com
Valuation
Metric | ROIV |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.41 |
Price/Sales | 716.32 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ROIV |
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 15.56 |
Interest Coverage | — |
Quick Ratio
ROIV
Profitability
Metric | ROIV |
|---|---|
Return on Assets (Normalized) | −14.59% |
Return on Equity (Normalized) | −17.91% |
Return on Invested Capital (Normalized) | −22.77% |
Return on Assets
ROIV
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|y?J<^&T | LOCK|#?>yw | $139B | |||
| Moderna Inc MRNA | LOCK|KDTx^< | LOCK|@<< | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|&^fG$d | LOCK|^@>y$ | $95B | |||
| argenx SE ADR ARGX | LOCK|?CVFkH | LOCK|M# | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?D!FfQ | LOCK|x#D | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|#<C@!PGC | LOCK|KtTG | $31B | |||
| Incyte Corp INCY | LOCK|!DzT%& | LOCK|g# | $25B | |||
| BioNTech SE ADR BNTX | LOCK|Nb%Q<Q | LOCK|?Y | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|d?!<G# | LOCK|qR&<B | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|z%!<^c | LOCK|#>c | $16B |
United States